Predictive biomarkers for treatment selection: statistical considerations

被引:17
作者
Chen, James J. [1 ,2 ]
Lu, Tzu-Pin [3 ]
Chen, Yu-Chuan [1 ]
Lin, Wei-Jiun [4 ]
机构
[1] US FDA, Natl Ctr Toxicol Res, Div Bioinformat & Biostat, Jefferson, AR 72079 USA
[2] China Med Univ, Grad Inst Biostat, Taichung, Taiwan
[3] Natl Taiwan Univ, Inst Epidemiol & Prevent Med, Dept Publ Hlth, Taipei 10764, Taiwan
[4] Feng Chia Univ, Dept Appl Math, Taichung 40724, Taiwan
关键词
biomarker adaptive design; personalized and precision medicine; predictive biomarker; predictive classifier; subgroup analysis; subgroup selection; SURROGATE END-POINTS; FALSE DISCOVERY RATE; GENE-EXPRESSION; CLINICAL-TRIALS; BONFERRONI PROCEDURE; DRUG DISCOVERY; MIXTURE MODEL; BREAST-CANCER; CLASSIFICATION; SAFETY;
D O I
10.2217/bmm.15.84
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Predictive biomarkers are developed for treatment selection to identify patients who are likely to benefit from a particular therapy. This review describes statistical methods and discusses issues in the development of predictive biomarkers to enhance study efficiency for detection of treatment effect on the selected responder patients in clinical studies. The statistical procedure for treatment selection consists of three components: biomarker identification, subgroup selection and clinical utility assessment. Major statistical issues discussed include biomarker designs, procedures to identify predictive biomarkers, classification models for subgroup selection, subgroup analysis and multiple testing for clinical utility assessment and evaluation.
引用
收藏
页码:1121 / 1135
页数:15
相关论文
共 94 条
  • [1] Technology Insight: tuning into the genetic orchestra using microarrays - limitations of DNA microarrays in clinical practice
    Abdullah-Sayani, Arnbreen
    Bueno-de-Mesquita, Jolien M.
    van de Vijver, Marc J.
    [J]. NATURE CLINICAL PRACTICE ONCOLOGY, 2006, 3 (09): : 501 - 516
  • [2] Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
    Amado, Rafael G.
    Wolf, Michael
    Peeters, Marc
    Van Cutsem, Eric
    Siena, Salvatore
    Freeman, Daniel J.
    Juan, Todd
    Sikorski, Robert
    Suggs, Sid
    Radinsky, Robert
    Patterson, Scott D.
    Chang, David D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) : 1626 - 1634
  • [3] Integration and use of biomarkers in drug development, regulation and clinical practice: a US regulatory perspective
    Amur, Shashi
    Frueh, Felix W.
    Lesko, Lawrence J.
    Huang, Shiew-Mei
    [J]. BIOMARKERS IN MEDICINE, 2008, 2 (03) : 305 - 311
  • [4] [Anonymous], OPT FDAS REG OV NEXT
  • [5] [Anonymous], DRUG DIAGN IN PRESS
  • [6] [Anonymous], STAFF QUAL PROC DRUG
  • [7] [Anonymous], GUID IND GUID IND AD
  • [8] [Anonymous], 1984, WADSWORTH INC
  • [9] [Anonymous], INT C HARM ICH GUID
  • [10] [Anonymous], STAT BIOSCI